Shilpa Kauta, MD
Neurology · Newark, DENPI 1649434283
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,450 of the $6,771 with a category attached, or 65.7%. Jazz Pharmaceuticals Inc. accounts for 63.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $2,290 and has fallen 87.9% since, to $277 in 2025.
Across 27 payments — averaging $250.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$4K
- Inspire Medical Systems, Inc.$2K
- Avadel CNS Pharmaceuticals, LLC$229
- Eisai Inc.$125
- Harmony Biosciences LLC$62
- Sunovion Pharmaceuticals Inc.$36
- plus $80 from 4 others
What the payments were for
- Consulting fees$4,45066%
- Travel & lodging$1,35420%
- Food & beverage$96614%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 3 | $4,281 |
| Inspire Medical Systems, Inc. | 12 | $1,958 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $229 |
| Eisai Inc. | 1 | $125 |
| Harmony Biosciences LLC | 3 | $62 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Greenwich Biosciences, Inc. | 1 | $29 |
| Neurelis, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $16 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XYWAV$4,250
- Inspire$1,057
- Inspire Upper Airway Stimulation System$678
- LUMRYZ$200
How this compares
$6,771 in reported general payments places this provider in the 85th percentile of 61 neurology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WakixPitolisant Hcl | 16 | $111,759 |
| HorizantGabapentin Enacarbil | 11 | $8,333 |
| QuviviqDaridorexant Hcl | 16 | $7,689 |
| DayvigoLemborexant | 18 | $5,402 |
| Pramipexole ErPramipexole Di-Hcl | 17 | $5,108 |
| Gabapentin | 212 | $3,261 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 95 | $1,679 |
| Pregabalin | 66 | $1,467 |
| Ropinirole ErRopinirole Hcl | 17 | $1,018 |
| Clonazepam | 87 | $973 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $941 |
| Eszopiclone | 29 | $878 |
| Ropinirole Hcl | 37 | $873 |
| Modafinil | 14 | $510 |
| Methylphenidate Hcl | 21 | $416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $62 | $111,75916 claims |
| Eisai Inc.Dayvigo | $125 | $5,40218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 61 neurology providers in Delaware.
Other neurology in Newark
- Justin MartelloNewark$485K
- Jason SilversteenNewark$202K
- Etsegenet TizazuNewark$15K
- William SommersNewark$14K
- Lee DresserNewark$12K
- John PollardNewark$7K
- Brian OommenNewark$2K
- Huijun WangNewark$1K
- Muhammad AfzalNewark$1K
- Sandeep DevarapalliNewark$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.